SMMT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
214.6M
-2.7%
220.5M
+13.0%
195.2M
-13.2%
224.9M
-4.0%
234.2M
R&D
169.1M
+7.2%
157.7M
+18.9%
132.6M
-10.0%
147.3M
+12.4%
131.1M
SG&A
45.5M
-27.5%
62.8M
+0.3%
62.6M
-19.4%
77.6M
-24.7%
103.1M
Operating Income
-214611000
+2.7%
-220496000
-13.0%
-195212000
+13.2%
-224925000
+4.0%
-234211000
EBITDA
-214526000
+2.7%
-220450000
-13.0%
-195168000
+13.2%
-224883000
+4.0%
-234169000
Net Income
-208385000
+3.4%
-215666000
-13.9%
-189424000
+13.6%
-219172000
+5.4%
-231793000
EPS (Basic)
$-0.26
+7.1%
$-0.28
-16.7%
$-0.24
+17.2%
$-0.29
+6.5%
$-0.31
EPS (Diluted)
$-0.26
+7.1%
$-0.28
-16.7%
$-0.24
+17.2%
$-0.29
+6.5%
$-0.31
Shares (Diluted)
798.2M
+2.6%
778.2M
+0.4%
775.5M
+1.1%
766.7M
+3.1%
743.4M
Summit Therapeutics (SMMT) — Financials